China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
Baxter International Inc. (NYSE:BAX), currently trading at $23.13 and rated with a GOOD financial health score according to InvestingPro, announced that Heather Knight, Executive Vice President, Chief Operating Officer, and interim group president of Medical Products and Therapies, has notified the company of her decision to resign. According to a statement made in a Securities and Exchange Commission filing, Knight’s resignation will be effective October 29, 2025. The company reported that Knight is leaving to join another organization in the healthcare industry.
Following Knight’s departure, Andrew Hider, Baxter’s President and Chief Executive Officer, will take on the additional responsibility of interim group president of Medical Products and Therapies, effective as of the transition date. Baxter also stated that it will no longer have a Chief Operating Officer position after Knight’s exit.
This information is based on a press release statement included in Baxter International’s SEC filing.
In other recent news, Baxter International Inc. reported its earnings for the second quarter of 2025, which fell short of analysts’ expectations. The company posted an earnings per share (EPS) of $0.59, slightly below the anticipated $0.61, marking a 3.28% negative surprise. Revenue also missed projections, coming in at $2.81 billion against the expected $2.82 billion. Additionally, Baxter has been recognized with a Gold Level Resiliency Badge by the Healthcare Industry Resilience Collaborative for its work in IV Solutions, Nutrition Solutions, and Premix Drugs. This distinction highlights Baxter’s robust supply chain practices. Meanwhile, the U.S. Commerce Department has initiated a national security investigation into medical equipment and devices, impacting several major manufacturers, including Baxter. This investigation has created uncertainty within the medical device sector, as noted by Needham. These developments reflect significant activities surrounding Baxter International in recent times.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.